English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back.
Tag: non-small cell lung cancer (NSCLC)
Results of Early Monitoring of Circulating Tumor DNA in Resected Early-Stage Non-Small Cell Lung Cancer
Among the questions that cancer patients ask following their surgeries are, “Will it come back? Do I need additional treatment?”
New Lung Immuno-oncology Therapeutic Strategy Identified
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells (the so-called protectors of the immune system). It was described in the April 20 online issue of Nature Immunology.
Wake Forest University School of Medicine Receives $2.7 Million Grant from National Cancer Institute to Study Lung Cancer Disparities
Wake Forest University School of Medicine has been awarded a five-year, $2.7 million grant from the National Cancer Institute to investigate lung cancer health disparities. Researchers will focus on developing novel treatments that target genetic, immunologic and metabolic changes that disproportionally affect Black patients with non-small cell lung cancer (NSCLC).
Poziotinib is active in EGFR exon 20 mutant non-small cell lung cancer with efficacy highly dependent on insertion location
A Phase II clinical trial of poziotinib for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 mutations, led by researchers at The University of Texas MD Anderson Cancer Center, found the drug had significant antitumor activity and the efficacy was highly dependent on the location of the exon 20 loop insertion, which may impact future clinical trials for EGFR exon 20 targeted therapies.
NCCN Announces Funding for Early-Stage Non-Small Cell Lung Cancer Projects, in Collaboration with AstraZeneca
The National Comprehensive Cancer Network’s Oncology Research Program to oversee projects focused on improving patient care and outcomes in early-stage non-small cell lung cancer in collaboration with AstraZeneca.
Black Lung Cancer Patients Die Sooner than White Counterparts
Structural racism thwarts a large proportion of black patients from receiving appropriate lung cancer care, resulting in worse outcomes and shorter lifespans than white patients with the disease, according to research presented at the 57th Annual Meeting of The Society of Thoracic Surgeons.
Those Living in Rural Areas, Uninsured or on Medicaid Less Likely to Receive Recommended Lung Cancer Treatment
Keck Medicine of USC study reveals that non-small cell lung cancer patients with pathologic N1 disease were less likely to receive chemotherapy if they lived in rural areas or were on Medicaid or uninsured.